MAGI2 and focal segmental glomerulosclerosis: Due to the specific regulation of MAGI2 depending on the podocytopathy investigated, we propose a role for MAGI2 as a molecular discriminator between FSGS and MCD and its use as an early marker for disruption of the glomerular filtration barrier.